Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 5Phase 1/2 5

Status

Completed 3Active not recruiting 2

Sponsor Class

INDUSTRY 4NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 42Genitourinary 36Gastrointestinal 34Other hematologic neoplasm 32Breast 32Lymphoid 31Gynecologic 18Plasma cell 15Classical hematology 11Dermatologic 10Myeloid 7Endocrine 5Sarcoma 4Head & Neck 4CNS 3Tumor-Agnostic 2NET 2Other solid neoplasm 1

Conditions

Neuroendocrine Tumors 2Neoplasms 2Multiple Endocrine Neoplasia Type 1 2Breast Neoplasms 2Thyroid cancer, follicular 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Non functioning pancreatic endocrine tumor 1Neoplasms by Site 1Breast Diseases 1Adenoma, Islet Cell 1Adenocarcinoma, Follicular 1

Interventions

cabozantinib 2Fulvestrant 2ribociclib 1lutetium Lu 177 dotatate 1X-Rays 1Specimen Handling 1Phantoms, Imaging 1Octreotide 1Magnetic Resonance Spectroscopy 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Has announcements × Endocrine × Clear all
NCT03375320 2026-05-01

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT03690388 2025-09-25

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Exelixis

Phase 3 Active not recruiting
187 enrolled 13 charts 1 FDA
EndocrineHead & Neck

Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT02437318 2025-02-13

SOLAR-1

Novartis

Phase 3 Completed
572 enrolled 22 charts 1 FDA
BreastEndocrine

Breast Neoplasms, Neoplasms, Multiple Endocrine Neoplasia Type 1

NCT02422615 2023-11-30

MONALEESA-3

Novartis

Phase 3 Completed
726 enrolled 17 charts 1 FDA
BreastEndocrine

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Multiple Endocrine Neoplasia Type 1

NCT01578239 2022-04-04

NETTER-1

Advanced Accelerator Applications

Phase 3 Completed
231 enrolled 16 charts 2 FDA
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡